Evidence map›Paper›PMID 39233645›Full record

ArticleCancer reports (Hoboken, N.J.)2024

Programmed death-ligand 1 expression in patients with primary or secondary myelofibrosis.

Moayed Ibrahim, Catherine Murphree, Kirtesh Patel, Matthew Mastrodomenico, Nakhle S Saba, Hana Safah, Janet Schmid, Francisco Socola

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Moayed IbrahimSection of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA.ORCID 0000-0003-0355-2380
Catherine MurphreeSection of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA.
Kirtesh PatelDelta Pathology Group, Shreveport, Louisiana, USA.
Matthew MastrodomenicoDelta Pathology Group, Shreveport, Louisiana, USA.
Nakhle S SabaSection of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA.
Hana SafahSection of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University, New Orleans, Louisiana, USA.
Janet SchmidPathology Department, Tulane University, New Orleans, Louisiana, USA.
Francisco SocolaHematology and Bone Marrow Transplant, University of California Davis, Sacramento, California, USA.ORCID 0000-0002-4002-9284

Funding

Carol Lavin Bernick Faculty Grant Program at Tulane University School of Medicine
6 · The paper itself

Abstract

backgroundIt has been described in mice models that myeloproliferative neoplasm (MPN) with JAK2-V617F mutation has an increased expression of programmed death-ligand 1 (PD-L1) in megakaryocytes leading to cancer immune evasion by inhibiting the T-lymphocytes.

aimsTo quantify and compare the PD-L1 expression on bone marrow (BM) of patients with MPN JAK2 positive, negative, and normal controls.

methodsWe collected BM of patients with MPN JAK2 positive, negative and normal controls from 1990 to 2019. We also created a scoring system to quantify PD-L1 expression in megakaryocytes.

resultsWe obtained 14 BM with JAK2 positive PMF, 5 JAK2 negative PMF, and 10 patients with normal BM biopsies. PD-L1 expression was higher in the JAK2 positive group compared with the control group with a score of 212.6 versus 121.1 (t-value 2.05, p-value 0.025). In addition, the score was higher in the PMF group regardless of JAK2 mutational status when compared with the control group with score of 205.9 versus 121.1 (t-value 2.12, p-value 0.021). There was no difference in the PD-L1 score between the JAK2 negative versus the control group 187.2 versus 121.1 (t-value 1.02, p-value 0.162).

conclusionThese findings suggest that PMF patients with a JAK2 mutation have a higher PD-L1 expression in megakaryocytes compared with the control group. We postulate that the combination of checkpoint and JAK2 inhibitors may be an active treatment option in JAK2 mutated PMF given the higher PD-L1 expression.

Indexed as

B7-H1 AntigenJanus Kinase 2Primary MyelofibrosisAdultAgedAged, 80 and overBone MarrowCase-Control StudiesFemaleHumansMaleMegakaryocytesMiddle AgedMutationB7-H1 AntigenCD274 protein, humanJAK2 protein, humanJanus Kinase 2immunotherapyJAK/STAT pathwayPD‐L1primary myelofibrosissecondary myelofibrosis

Identifiers

PMID39233645
PMCPMC11375330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.